Skip to main content

Table 2 Studies with switch to a different agent after a platinum-based induction

From: Maintenance therapy in NSCLC: why? To whom? Which agent?

First Author (N of randomized pts to maintenance)

Maintenance Schema

Primary End Point

Median PFS (mo)

P value

Median OS (months)

P value

References

Fidias P. (309)

Immediate vs delayed docetaxel

OS

5.7 vs 2.7

0.0001

12.3 vs 9.7

0.08

[26]

Ciuleanu T. (663)

Pemetrexed vs placebo

PFS

4.3 vs 2.6

0.0001

13.4 vs 10.6

0.012

[27]

Cappuzzo F. (889)

Erlotinib vs placebo

PFS

12.3 vs 11.1

0.0001

12 vs 11

0.063

[31]

Perol M. (464)

Gemcitabine vs erlotinib vs placebo

PFS

3.7 vs 2.8 vs 2.1

nr

HR 0.86 vs 0.81

na

[21]

Kabbinavar F.* (768)

Bevacizumab ± Erlotinib

PFS

4.8 vs 3.7

0.006

Na

na

[32]

Gaafar RM (173)

Gefitinib vs placebo

OS

4.1 vs 2.9

0.0015

Na

na

[33]

  1. *In this trial bevacizumab was already present in the induction therapy
  2. nr: not reported, na: not available